Today's press release:
IMUTEC PHARMA ANNOUNCES COMPLETION
OF CLINICAL TRIAL ENROLLMENT
TSE / ME: IMT
NASDAQ: IMUTF
TORONTO, ONTARIO March 11, 1998 - Imutec Pharma Inc. today announced
that it has completed patient enrollment for its Phase I/II pancreatic
cancer trial at the Rush Presbyterian St. Luke's Medical Center in
Chicago.
The completion of this Phase I/II trial marks the achievement of an
other significant milestone by Imutec Pharma. The results of this trial
will aid in discussions with potential partners regarding the licensing
of marketing and distribution rights for Virulizinr, which is in line
with the Company's business strategy of out-licensing products prior to
Phase III clinical trials.
"I am pleased to report that enrollment of our current trial is now
complete," said Philippe Lacaille, President & CEO at Imutec Pharma.
"The required number of evaluable patients have completed the treatment
period, according to the design of the study. We will now be able to
complete the data analysis in order to determine the safety and efficacy
of Virulizinr. We anticipate being able to communicate these results
shortly."
In July 1996, Imutec Pharma initiated a Phase I/II clinical trial to
evaluate the biological activity of Virulizinr in patients with
pancreatic cancer, and to monitor the safety and efficacy of the
treatment. The trial was designed as a non-comparative, escalating dose
study involving advanced stage patients who had failed standard or
investigational treatments. In November, 1997, Imutec Pharma reported an
interim efficacy analysis of its current Phase I/II trial. The data
obtained at that time indicated the same trend in safety and efficacy as
seen in Imutec's previous pancreatic cancer study.
Imutec Pharma Inc. is a pharmaceutical company engaged in the
development and commercialization of innovative products for the
treatment of cancer and certain viral diseases. Through an active
acquisition and in-licensing program, Imutec Pharma's goal is to build
and clinically develop a portfolio of innovative drugs targeted at
life-threatening diseases. Thereafter, Imutec Pharma intends to
undertake late stage clinical development and marketing in cooperation
with strategic pharmaceutical partners. Founded in 1986, Imutec Pharma
Inc. is a public company listed on the Toronto Stock Exchange and the
Montreal Stock Exchange under the symbol IMT and on the NASDAQ exchange
under the symbol IMUTF.
Except for historical information, this press release contains
forward-looking statements which reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risks and uncertainties which may cause actual results to differ
materially from those statements. Those risks and uncertainties include,
but are not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new product
development, uncertainties related to the regulatory approval process,
and other risks detailed from time-to-time in the Company's ongoing
quarterly filings, annual reports and 20-F filings.
Imutec Pharma's press releases are available through the Company's
Internet site: imutec.com
For further information, please contact:
Paul W. Truscott, Jr.
Associate, Corporate Communications
Imutec Pharma, Inc.
1285 Morningside Avenue
Scarborough, ON
M1B 3W2
Tel 416-724-1100 x251
Fax 416-724-1167 |
